November 29, 2016
(Wired) – But the jury’s still out on whether Crispr will be as transformative as a medical therapy as it has been as lab tool. Plenty of gene-editing techniques have been attempted as therapies, but few have made significant impacts—especially when it comes to diseases as complex as cancer. A better place to start testing gene therapies is with inherited blood disorders, like sickle cell anemia and beta thalassemia.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.